Protalix BioTherapeutics (NYSE:PLX - Get Free Report) released its earnings results on Friday. The company reported ($0.05) EPS for the quarter, RTT News reports. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%.
Protalix BioTherapeutics Stock Down 15.1%
Shares of NYSE:PLX traded down $0.26 during midday trading on Monday, reaching $1.46. The company had a trading volume of 5,670,821 shares, compared to its average volume of 514,217. The business's 50 day moving average price is $2.54 and its 200 day moving average price is $2.16. The stock has a market cap of $116.09 million, a PE ratio of -11.23 and a beta of -0.05. Protalix BioTherapeutics has a 1-year low of $0.82 and a 1-year high of $3.10.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on PLX shares. HC Wainwright increased their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th.
Get Our Latest Stock Analysis on Protalix BioTherapeutics
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
See Also
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
